Lisata Therapeutics’ (LSTA) Hold Rating Reaffirmed at Brookline Capital Management

Brookline Capital Management reiterated their hold rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a research note released on Wednesday,Benzinga reports.

A number of other research analysts also recently commented on the stock. Zacks Research downgraded shares of Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $23.50.

Lisata Therapeutics Stock Up 86.6%

LSTA stock opened at $4.03 on Wednesday. Lisata Therapeutics has a 52-week low of $1.81 and a 52-week high of $4.17. The stock’s fifty day simple moving average is $2.07 and its 200-day simple moving average is $2.34. The stock has a market capitalization of $35.54 million, a price-to-earnings ratio of -1.89 and a beta of 1.11.

Lisata Therapeutics (NASDAQ:LSTA) last released its earnings results on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.05. As a group, analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

Institutional investors have recently bought and sold shares of the business. Cerity Partners LLC acquired a new stake in shares of Lisata Therapeutics in the second quarter worth $32,000. CIBC Bancorp USA Inc. purchased a new stake in Lisata Therapeutics during the 3rd quarter worth $37,000. Finally, Ground Swell Capital LLC purchased a new stake in Lisata Therapeutics during the 3rd quarter worth $62,000. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Lisata Therapeutics

Here are the key news stories impacting Lisata Therapeutics this week:

• Positive Sentiment: Lisata agreed to be acquired by Kuva Labs for $4.00 per share in cash via a tender offer; the term sheet is binding and the companies expect a definitive purchase agreement before Feb. 27, 2026. This is the primary driver of today’s rally. GlobeNewswire
• Positive Sentiment: The cash offer equals roughly an 85% premium to the recent closing price; shareholders are also to receive two non-tradeable contingent value rights (CVRs) worth $1 each if milestones are met — including IP reversion in Greater China and an NDA filing — bringing potential total consideration to ~180% of the prior close. Investing.com
• Positive Sentiment: The boards of both companies unanimously approved the term sheet; Kuva previously licensed Lisata’s lead candidate, certepetide, indicating strategic fit between Lisata’s peptide platform and Kuva’s NanoMark imaging/development programs. Quiver Quant
• Neutral Sentiment: The tender offer has not yet commenced — full details will come in SEC filings (Schedule TO and a Schedule 14D‑9). Investors should wait for those documents for definitive terms and timelines. GlobeNewswire
• Neutral Sentiment: Trading was briefly halted for news pending; intraday volume spiked well above average as market participants reacted to the takeover news — this increases short‑term volatility.
• Neutral Sentiment: Analysts: Brookline Capital Management reaffirmed a “hold” rating, indicating at least one shop sees the deal as fairly priced or that uncertainty remains. Benzinga
• Negative Sentiment: Shareholder litigation risk: Halper Sadeh LLC is investigating whether the sale is fair to shareholders — such actions can delay completion, increase costs, or pressure deal terms. Business Wire
• Negative Sentiment: Deal risks remain: the tender offer and merger depend on customary closing conditions, potential competing bids, and regulatory milestones tied to CVRs — any failure or contest could reduce expected value or prolong uncertainty. Proactive Investors

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.